Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by KM Gooden
Prm21 - Modelling Survival of Patients With Completely Resected Advanced Melanoma With Adjuvant Treatment of Nivolumab Versus Observation
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
JAMA Oncology
Cancer Research
Oncology
Nivolumab Improves Survival for Patients With Advanced Lung Cancer
Cancer
Cancer Research
Oncology
Dramatic Survival Benefit With Nivolumab in Melanoma
Cancer Discovery
Oncology
Adherence and Feasibility of 2 Treatment Schedules of S-1 as Adjuvant Chemotherapy for Patients With Completely Resected Advanced Lung Cancer: A Multicenter Randomized Controlled Trial
BMC Cancer
Cancer Research
Oncology
Genetics
Ipilimumab Combined With Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
Clinical Cancer Research
Cancer Research
Oncology
Baseline Neutrophil-To-Lymphocyte Ratio (NLR) and Derived NLR Could Predict Overall Survival in Patients With Advanced Melanoma Treated With Nivolumab
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Association of Adjuvant Chemoradiotherapy vs Radiotherapy Alone With Survival in Patients With Resected Major Salivary Gland Carcinoma
JAMA Otolaryngology - Head and Neck Surgery
Medicine
Otorhinolaryngology
Surgery
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
JAMA Oncology
Cancer Research
Oncology
